<DOC>
	<DOCNO>NCT00258843</DOCNO>
	<brief_summary>To describe tolerance term occurrence serious adverse reaction severe adverse reaction ( injection site systemic ) within eight day one dose IMOVAX Polio™ administer child infant .</brief_summary>
	<brief_title>Safety Imovax Polio Chinese Infants Children</brief_title>
	<detailed_description />
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Group 1 : Aged 18 month ( 1820 month ) day inclusion Group 2 : Aged 2 month ( 5670 day ) day inclusion Participation another clinical trial 4 week precede trial vaccination Planned participation another clinical trial present trial period Congenital acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy Systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance Chronic illness stage could interfere trial conduct completion Blood bloodderived product receive past 3 month ( Group 1 ) since birth ( Group 2 ) Any vaccination 4 week precede trial vaccination ( except BCG Hepatitis B [ Hep B ] Group 2 ) Vaccination plan 4 week follow trial vaccination Group 1 : Previous booster vaccination poliomyelitis infection trial vaccine another vaccine . Group 2 : Previous vaccination poliomyelitis infection trial vaccine another vaccine . History poliomyelitis infection ( confirm either clinically , serologically microbiologically ) Clinical serological evidence systemic illness include Hepatitis B , C HIV Thrombocytopenia bleed disorder contraindicate intramuscular vaccination History of/current seizure Febrile illness ( axillary temperature ≥ 37.4°C ) acute illness day inclusion</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>IMOVAX ;</keyword>
	<keyword>poliomyelitis</keyword>
</DOC>